Company Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.
It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.
The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.
It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 188 |
| CEO | Dr. Gavin MacBeath Ph.D. |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts United States | |
| Website | https://www.tscan.com |
Stock Details
| Ticker Symbol | TCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783328 |
| CUSIP Number | 89854M101 |
| ISIN Number | US89854M1018 |
| Employer ID | 82-5282075 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gavin MacBeath Ph.D. | Chief Executive Officer & Director |
| Dr. Justin McCue Ph.D. | Chief Technology Officer |
| Jason A. Amello CPA | Chief Financial Officer & Treasurer |
| Ann Hargraves | Senior Vice President of Human Resources |
| Dr. Shrikanta Chattopadhyay M.D. | Senior Vice President & Head of Translational Medicine |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal & Strategy Officer and Company Secretary |
| Jim Murray | Senior Vice President & Head of Development Operations |
| Ray Lockard M.B.A. | Senior Vice President & Head of Quality |
| Tomasz Kula Ph.D. | Co-Founder & Member of Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | 4 | Filing |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 26, 2024 | 424B5 | Filing |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 16, 2024 | 4 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |